{"id":"metaclazepam","rwe":[{"pmid":"15329838","year":"2004","title":"Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.","finding":"","journal":"Journal of mass spectrometry : JMS","studyType":"Clinical Study"},{"pmid":"8104405","year":"1993","title":"Synthesis and receptor binding studies of 2-functionalized 1,4-benzodiazepine derivatives as potential metaclazepam-like antianxiety agents.","finding":"","journal":"Farmaco (Societa chimica italiana : 1989)","studyType":"Clinical Study"},{"pmid":"2575907","year":"1989","title":"Transfer of metaclazepam and its metabolites into breast milk.","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"},{"pmid":"2568645","year":"1989","title":"Double-blind study of metaclazepam versus diazepam treatment of outpatients with anxiety syndrome.","finding":"","journal":"Pharmacopsychiatry","studyType":"Clinical Study"},{"pmid":"2905134","year":"1988","title":"[Plasma digoxin levels following treatment with metaclazepam].","finding":"","journal":"Arzneimittel-Forschung","studyType":"Clinical Study"}],"tags":[{"label":"metaclazepam","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"ka 2527","offLabel":[],"synonyms":["metaclazepam","brometazepam","metuclazepam","metaclazepam hydrochloride","metaclazepam HCl","Ka-2527","Ka 2527"],"timeline":[],"approvals":[],"brandName":"Ka 2527","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"metaclazepam","explanation":"Imagine your brain is a busy city with many different streets and intersections. Neurotransmitters are like the traffic signals that help different parts of the brain communicate with each other. Metaclazepam is believed to affect these traffic signals, helping to regulate the flow of information and potentially reducing anxiety or other symptoms.","oneSentence":"Metaclazepam is thought to work by modulating the activity of neurotransmitters in the brain.","technicalDetail":"Metaclazepam is a benzodiazepine derivative that acts as a GABA_A receptor agonist, enhancing the activity of the inhibitory neurotransmitter GABA and leading to sedative, anxiolytic, and muscle relaxant effects."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1716","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=METACLAZEPAM","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T14:20:55.185726","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:16:08.737393+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[],"genericName":"metaclazepam","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"006786","UNII":"C2N2B1303L","CHEBI":"CHEBI:135621","INN_ID":"4495","RXNORM":"29590","UMLSCUI":"C1619621","ChEMBL_ID":"CHEMBL1290783","PUBCHEM_CID":"71272","SECONDARY_CAS_RN":"61802-93-5","MESH_SUPPLEMENTAL_RECORD_UI":"C036366"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":19,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[{"date":"2004 Aug","pmid":"15329838","title":"Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization.","journal":"Journal of mass spectrometry : JMS"},{"date":"1993 Jul","pmid":"8104405","title":"Synthesis and receptor binding studies of 2-functionalized 1,4-benzodiazepine derivatives as potential metaclazepam-like antianxiety agents.","journal":"Farmaco (Societa chimica italiana : 1989)"},{"date":"1989 Nov","pmid":"2575907","title":"Transfer of metaclazepam and its metabolites into breast milk.","journal":"Arzneimittel-Forschung"},{"date":"1989 May","pmid":"2568645","title":"Double-blind study of metaclazepam versus diazepam treatment of outpatients with anxiety syndrome.","journal":"Pharmacopsychiatry"},{"date":"1988 Jul","pmid":"2905134","title":"[Plasma digoxin levels following treatment with metaclazepam].","journal":"Arzneimittel-Forschung"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Metaclazepam, a small molecule belonging to the drug class of metaclazepam, is a medication with unknown target and commercial status. Its mechanism of action is not well-documented, and it is not approved by the FDA for any indications. As a result, there is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Further research is needed to fully understand the properties and potential uses of metaclazepam. Due to the lack of information, it is not possible to provide a comprehensive summary of its safety considerations.","enrichmentLevel":5,"visitCount":0,"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T11:16:08.737393+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}